| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* The Wistar Institute, and
Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104
E1-deleted adenoviral recombinants most commonly based on the human serotype 5 (AdHu5) have been shown thus far to induce unsurpassed transgene product-specific CD8+ T cell responses. A large percentage of the adult human population carries neutralizing Abs due to natural exposures to AdHu5 virus. To circumvent reduction of the efficacy of adenovirus (Ad) vector-based vaccines by neutralizing Abs to the vaccine carrier, we developed E1-deleted adenoviral vaccine carriers based on simian serotypes. One of these carriers, termed AdC68, expressing a codon-optimized truncated form of gag of HIV-1 was shown previously to induce a potent transgene product-specific CD8+ T cell response in mice. We constructed a second chimpanzee adenovirus vaccine vector, termed AdC6, also expressing the truncated gag of HIV-1. This vector, which belongs to a different serotype than the AdC68 virus, induces high frequencies of gag-specific CD8+ T cells in mice including those pre-exposed to AdHu5 virus. Generation of an additional E1-deleted adenoviral vector of chimpanzee origin allows for sequential booster immunizations with heterologous vaccine carriers. In this study, we show that such heterologous prime boost regimens based on E1-deleted adenoviral vectors of different serotypes expressing the same transgene product are highly efficient in increasing the transgene product-specific CD8+ T cell response. They are equivalent to sequential vaccinations with an E1-deleted Ad vector followed by booster immunization with a poxvirus vector and they surpass regimens based on DNA vaccine prime followed by a recombinant adenoviral vector boost.
This article has been cited by other articles:
|
|
 |
|
  L. H. Haut and H. C. J. Ertl Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine J. Leukoc. Biol., October 1, 2009; 86(4): 779 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tatsis, M. O. Lasaro, S.-W. Lin, Z. Q. Xiang, D. Zhou, L. DiMenna, H. Li, A. Bian, S. Abdulla, Y. Li, et al. Adenovirus Vector-Induced Immune Responses in Nonhuman Primates: Responses to Prime Boost Regimens J. Immunol., May 15, 2009; 182(10): 6587 - 6599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, B. A. Ewald, D. M. Lynch, M. Denholtz, P. Abbink, A. A. C. Lemckert, A. Carville, K. G. Mansfield, M. J. Havenga, J. Goudsmit, et al. Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys J. Virol., May 15, 2008; 82(10): 4844 - 4852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Schoenly and D. B. Weiner Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business" J. Virol., April 1, 2008; 82(7): 3166 - 3180. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Holst, C. Bartholdy, A. Stryhn, A. R. Thomsen, and J. P. Christensen Rapid and sustained CD4+ T-cell-independent immunity from adenovirus-encoded vaccine antigens J. Gen. Virol., June 1, 2007; 88(6): 1708 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Abbink, A. A. C. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D J. Virol., May 1, 2007; 81(9): 4654 - 4663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Havenga, R. Vogels, D. Zuijdgeest, K. Radosevic, S. Mueller, M. Sieuwerts, F. Weichold, I. Damen, J. Kaspers, A. Lemckert, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J. Gen. Virol., August 1, 2006; 87(Pt 8): 2135 - 2143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tang and G. G. Maul Mouse cytomegalovirus crosses the species barrier with help from a few human cytomegalovirus proteins. J. Virol., August 1, 2006; 80(15): 7510 - 7521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Buffa, D. R. M. Negri, P. Leone, R. Bona, M. Borghi, I. Bacigalupo, D. Carlei, C. Sgadari, B. Ensoli, and A. Cara A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice J. Gen. Virol., June 1, 2006; 87(6): 1625 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Gao, A. C. Soloff, X. Lu, A. Montecalvo, D. C. Nguyen, Y. Matsuoka, P. D. Robbins, D. E. Swayne, R. O. Donis, J. M. Katz, et al. Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization J. Virol., February 15, 2006; 80(4): 1959 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Barratt-Boyes, A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors J. Gen. Virol., January 1, 2006; 87(1): 139 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-p. Kong, L. Xu, K. Stadler, J. B. Ulmer, S. Abrignani, R. Rappuoli, and G. J. Nabel Modulation of the Immune Response to the Severe Acute Respiratory Syndrome Spike Glycoprotein by Gene-Based and Inactivated Virus Immunization J. Virol., November 15, 2005; 79(22): 13915 - 13923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hashimoto, J. L. Boyer, N. R. Hackett, J. M. Wilson, and R. G. Crystal Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity Infect. Immun., October 1, 2005; 73(10): 6885 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. C. Lemckert, S. M. Sumida, L. Holterman, R. Vogels, D. M. Truitt, D. M. Lynch, A. Nanda, B. A. Ewald, D. A. Gorgone, M. A. Lifton, et al. Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity J. Virol., August 1, 2005; 79(15): 9694 - 9701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wu, W.-p. Kong, and G. J. Nabel Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens J. Virol., July 1, 2005; 79(13): 8024 - 8031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, A. A. C. Lemckert, R. Vogels, J. H. H. V. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, et al. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein J. Immunol., June 1, 2005; 174(11): 7179 - 7185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Krebs, E. Scandella, B. Odermatt, and B. Ludewig Rapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus J. Immunol., April 15, 2005; 174(8): 4559 - 4566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Reyes-Sandoval, J. C. Fitzgerald, R. Grant, S. Roy, Z. Q. Xiang, Y. Li, G. P. Gao, J. M. Wilson, and H. C. J. Ertl Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes J. Virol., July 15, 2004; 78(14): 7392 - 7399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Barouch, M. G. Pau, J. H. H. V. Custers, W. Koudstaal, S. Kostense, M. J. E. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity J. Immunol., May 15, 2004; 172(10): 6290 - 6297. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
